NCT05996770View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of Azvudine and Paxlovid in the Treatment of Hospitalized Patients With COVID-19

Not yet recruitingOBSERVATIONAL

Enrollment

1,500

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

December 30, 2024

Conditions

PaxlovidAzvudineCOVID-19

All Listed Sponsors

lead

Xiao Li，MD

OTHER

NCT05996770 - Evaluation of the Safety and Efficacy of Azvudine and Paxlovid in the Treatment of Hospitalized Patients With COVID-19 | Biotech Hunter | Biotech Hunter